Abbott India DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.75×	0.75×	0.74×	0.75×
	1.14×	1.16×	1.17×	1.12×
	26.2%	25.3%	23.6%	21.2%
	1.12×	1.15×	1.20×	1.22×
	1.36×	1.40×	1.40×	1.43×
	34.2%	35.5%	34.6%	30.9%
	34.5%	35.7%	34.9%	31.6%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

ABBOTINDIA₹26,145.00

Abbott India Ltd.

· Pharma & Health

₹ CrorePeersPFIZER GLAXO IPCALAB AJANTPHARM ANTHEM MEDANTA GLENMARK BIOCON

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.75	0.74	0.75	0.75
Interest Burden (Pretax/EBIT) ×	1.12	1.17	1.16	1.14
EBIT Margin %	21.23	23.63	25.32	26.21
Asset Turnover ×	1.22	1.20	1.15	1.12
Financial Leverage (Assets/Equity) ×	1.43	1.40	1.40	1.36
ROE (5-step product, year-end total equity) %	30.94	34.60	35.48	34.17
ROE (owners' profit / average owners' equity) %	31.60	34.88	35.66	34.46

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.